$RADX News

HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Issues Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Announces That New Data From The Ongoing Phase 0/1 Heat Trial Evaluating 177Lu-RAD202, A First-In-Class HER2-targeted Radiopharmaceutical Therapy, Will Be Presented As A Poster At The American Association For Cancer Research Annual Meeting on April 17–22

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Announces Dosing Of Final Patient In Phase 2b Imaging Trial Evaluating RAD 101 In Individuals With Confirmed Recurrent Brain Metastases From Solid Tumors Of Different Origins

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics Advances Cancer Drug Trial After Safety Review

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Signs Supply Agreement With Siemens Healthineers For RAD101 In U.S. Phase 3 Trial After Phase 2b Shows 90% Concordance With MRI In Brain Metastases

Radiopharm Theranostics Signs Supply Agreement With Siemens Healthineers For RAD101 In U.S. Phase 3 Trial After Phase 2b Shows 90% Concordance With MRI In Brain Metastases

RADX: RAD 101 Phase IIb Interim Analysis

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Says First Patient Dosed In First-In-Human Phase 1 Clinical Trial Of RAD 402, Monoclonal Antibody Targeting KLK3 Radiolabelled With Terbium 161 Being Evaluated In Advanced Prostate Cancer

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks